Plain-English translation of NCT06216249 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new way to give 177Lu-PSMA-617, a radioactive treatment designed to target prostate cancer cells that have spread throughout the body. Instead of following the standard schedule of six treatments over six weeks, this study will compare two approaches: one group will receive up to 12 treatments with possible breaks when scans show the cancer is responding well, while the other group will follow the standard six-treatment schedule. The goal is to see if the flexible approach helps patients live longer and feel better.
Advanced prostate cancer that no longer responds to hormone therapy is difficult to treat, and doctors want to know if giving more doses of this medication with strategic breaks could improve how long patients survive and whether it controls the cancer better. Current treatment is limited to six cycles, but researchers believe extending treatment with breaks based on how well it's working might offer better results.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the flexible treatment schedule (up to 12 treatments over several months with possible breaks) or the standard schedule (6 treatments given every 6 weeks). You will receive intravenous infusions of the medication and undergo imaging scans (including PET scans) after each treatment to monitor how your cancer is responding. Throughout the study, you will also have blood tests to check your blood cell counts and kidney function, and you will be asked about your pain levels and overall quality of life.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States